Cancer drug development is a lengthy process; it can take as long as 15 years for a successful drug to reach to FDA (Food and Drug Administration) approval, going through all the different phases of pre-clinical and clinical research, ie, Phase I/II/III trials. It has been previously estimated that out of 10,000 chemical compounds initially tested in pre-clinical studies, only 5 are eventually assessed in clinical trials, and only one achieves to gain official approval. Furthermore, the final cost of the whole process until a drug reaches FDA approval has been approximately estimated to exceed $ 800,000,000. Cancer drug development starts with the identification of a relevant molecular target. Genetic instability as well as epigenetic changes is the driving force of tumorigenesis. Mutational activation of oncogenes or inactivation of tumor suppressor genes leads to malignant phenotypes.
Journal of Physical Medicine & Rehabilitation Open Access is one of the top online publishing journals for research from the field of Cancer Drug Development. The open access articles published in this scholarly journal are reviewed by at least two reviewers of the associated fields. The journal publishes original research articles, reviews, case reports, short communications, etc and emphasizes theoretical and experimental work. To ensure high quality articles, both editors and reviewers actively participate in the peer review process and help in completing the review process within 21 days. As an important educational platform the journal provides scientists and researchers access to the newest trends and research outlooks. Please browse through the list of peer-reviewed journals to find the scientific publication of your interest.
Last date updated on September, 2014